paclitaxel has been researched along with Cardiomyopathies in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonne, G; Chatzifrangkeskou, M; Gotthardt, M; Jüttner, R; Le Dour, C; Lefebvre, F; Macquart, C; Morales Rodriguez, B; Muchir, A; Schmitt, A | 1 |
| Beer, LA; Domchek, S; Kossenkov, AV; Ky, B; Liu, Q; Luning Prak, E; Speicher, DW | 1 |
| Assouline, D; Brun, O; Coeffic, D; Fric, D; Page, E; Winckel, P | 1 |
| Imai, H; Imanaka-Yoshida, K; Kamikura, Y; Saito, K; Sekine, T; Takeda, K | 1 |
| Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F | 1 |
| Benassi, A; Ewing, LG; Gioia, G; Levite, HA; Matthai, W; Rana, H | 1 |
| Thomas, M | 1 |
| Benassi, A; Dralle, J; Gillin, K; Gioia, G; Gioia, MF; Matthai, W; White, J | 1 |
| Takemoto, Y; Yoshiyama, M | 1 |
| Cheung, KL; Luk, IS; Ma, L; Shek, TW | 1 |
| Sparano, JA | 2 |
| Burtness, BA; Gollerkeri, A; Harrold, L; Jain, D; Rose, M | 1 |
| Ashby, M; Hudis, C; Keefe, D; Murphy, M; Paton, V; Pierri, MK; Seidman, A; Shak, S; Stewart, SJ | 1 |
| Becker, KJ; Burcham, GN; Hooser, SB; Tahara, JM; Wilson, CR | 1 |
3 review(s) available for paclitaxel and Cardiomyopathies
| Article | Year |
|---|---|
[Drug-induced cardiomyopathy].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cardiomyopathies; Cyclophosphamide; Humans; Interferon-alpha; Paclitaxel; Time Factors; Trastuzumab | 2007 |
Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Humans; Paclitaxel; Razoxane | 1998 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
3 trial(s) available for paclitaxel and Cardiomyopathies
| Article | Year |
|---|---|
Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cardiomyopathies; Docetaxel; Fatty Acids; Female; Humans; Iodine Radioisotopes; Iodobenzenes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Taxoids; Technetium Tc 99m Sestamibi | 2003 |
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2004 |
Cardiac dysfunction in the trastuzumab clinical trials experience.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Risk Factors; Trastuzumab | 2002 |
9 other study(ies) available for paclitaxel and Cardiomyopathies
| Article | Year |
|---|---|
Microtubule cytoskeleton regulates Connexin 43 localization and cardiac conduction in cardiomyopathy caused by mutation in A-type lamins gene.
Topics: Acetylation; Animals; Cardiac Conduction System Disease; Cardiomyopathies; Connexin 43; Cytoskeleton; Gap Junctions; Lamin Type A; Male; Mice; Mice, Knockout; Microtubules; Mutation; Myocardium; Myocytes, Cardiac; Paclitaxel | 2019 |
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cardiomyopathies; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Heart Failure; Humans; Immunoglobulin E; Immunoglobulin G; Middle Aged; Paclitaxel; Proteomics; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2016 |
Cardiac dysfunction in clinical trials of trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Trastuzumab | 2002 |
Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction.
Topics: Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Cardiomyopathies; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Female; Follow-Up Studies; Heart Failure; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Severity of Illness Index; Sirolimus; Stents; Stroke Volume; Survival Rate; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2006 |
Revascularization for ischemic LV dysfunction: stents or surgery?
Topics: Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Bypass; Humans; Myocardial Ischemia; Paclitaxel; Patient Selection; Prosthesis Design; Radiography; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2007 |
Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Retrospective Studies; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; United States; Ventricular Dysfunction, Left | 2007 |
Paclitaxel-induced cardiotoxicity. An ultrastructural study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Heart; Humans; Lymphatic Metastasis; Middle Aged; Myocardium; Paclitaxel | 1996 |
Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Doxorubicin; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ventricular Function, Left | 2001 |
Myocardial fibrosis associated with previous ingestion of yew (Taxus sp.) in a Holstein heifer: evidence for chronic yew toxicity in cattle.
Topics: Alkaloids; Animals; Cardiomyopathies; Cattle; Cattle Diseases; Fatal Outcome; Female; Histocytochemistry; Plant Poisoning; Rumen; Taxoids; Taxus | 2013 |